TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9196087

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 microg twice daily for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study: 1567346

Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 6
Study: 6423796

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (10.8 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without taurine supplementation)
Number of subjects: 20
Study: 31102881

Group type: EXPERIMENTAL
Intervention: Brief online feedback on alcohol use risk severity
Number of subjects: 724

Group type: COMPARATOR
Intervention: No-feedback condition
Number of subjects: 724
Study: 29648867

Group type: EXPERIMENTAL
Intervention: Pitch sequences with invariant secondary dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration sequences with invariant secondary dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch sequences with randomized secondary dimension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both pitch and duration sequences
Number of subjects: 0
Study: 27006514

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-sleep-deprived condition
Number of subjects: 14
Study: 25819980

Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health (WYHH) intervention; a 32-week community health promoter-facilitated walking group intervention, meeting three times per week for 45 to 90 minutes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lagged intervention (control) group; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health (WYHH) intervention; a 32-week community health promoter-facilitated walking group intervention.
Number of subjects: 0
Study: 23183514

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 20194413

Group type: EXPERIMENTAL
Intervention: Schizophrenia care management program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 18543135

Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM) in sedated patients
Number of subjects: 865

Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142) in sedated patients
Number of subjects: 865

Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142) in nonsedated patients
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM) in nonsedated patients
Number of subjects: 865
Study: 16329274

Group type: EXPERIMENTAL
Intervention: Cranberries
Number of subjects: 0
Study: 11860040

Group type: EXPERIMENTAL
Intervention: Cigarette abstinence for 31 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (continued to smoke)
Number of subjects: 96
Study: 10432174

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 8
Study: 8562738

Group type: EXPERIMENTAL
Intervention: Asymptomatic bacteriuria in women with diabetes mellitus
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Bacteriuric women
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Aboriginal women
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Urinary leukocyte counts
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Duration of diabetes and aboriginal origin
Number of subjects: 1072
Study: 2139282

Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (YDV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (PDV)
Number of subjects: 0
Study: 6343878

Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulfametrole (640 to 3200 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Five-day trimethoprim-sulfametrole (160 to 800 mg twice daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Five-day trimethoprim (200 mg twice daily)
Number of subjects: 95
Study: 31280772

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 33
Study: 30249589

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting hospital admissions
Number of subjects: 135

Group type: COMPARATOR
Intervention: Traditional symptom-counting algorithms
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting corticosteroid need
Number of subjects: 135

Group type: COMPARATOR
Intervention: Traditional algorithms
Number of subjects: 135
Study: 26220570

Group type: EXPERIMENTAL
Intervention: Fruit intake during weight loss
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vegetable intake during weight loss
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma carotenoid concentrations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intakes during weight loss
Number of subjects: 100
Study: 24994074

Group type: EXPERIMENTAL
Intervention: CBG1
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: CBG2
Number of subjects: 532
Study: 22113223

Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine (10 mg morphine and 0.5% bupivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol-bupivacaine (100 mg tramadol and 0.5% bupivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study: 20236904

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus SE (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Optibond Solo Plus (Group 5, Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tyrian SPE (Group 4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Prompt SE (Group 3)
Number of subjects: 40
Study: 17582567

Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-of-illness studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sociobehavioral studies
Number of subjects: 0
Study: 16762960

Group type: EXPERIMENTAL
Intervention: Iron sucrose 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg (outflow dialyser line)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg (inflow dialyser line)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15153728

Group type: EXPERIMENTAL
Intervention: Unilateral periprostatic lidocaine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous synthetic opioid (meperidine or tramadol) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sterile normal saline)
Number of subjects: 0
Study: 11004138

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reteplase
Number of subjects: 46
Study: 8623868

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 180
Study: 1483371

Group type: EXPERIMENTAL
Intervention: Indomethacin 1%
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group D (no NSAID)
Number of subjects: 164
Study: 3881220

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Doxapram
Number of subjects: 8
Study: 31711211

Group type: EXPERIMENTAL
Intervention: Higher intensity intervention (graded exercise test, feedback-monitoring devices)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher intensity intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Therapists' perspective
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patient perceptions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Therapists' perceptions
Number of subjects: 10
Study: 31894030

Group type: EXPERIMENTAL
Intervention: 5mg amlodipine
Number of subjects: 84

Group type: COMPARATOR
Intervention: 2.5mg levamlodipine
Number of subjects: 84
Study: 28903120

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management (CBCM)
Number of subjects: 268
Study: 25287762

Group type: EXPERIMENTAL
Intervention: Orodispersible L-carnosine (500 mg OD)
Number of subjects: 50
Study: 23426674

Group type: EXPERIMENTAL
Intervention: Stereo plaids presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different spatial frequency and contrast gratings
Number of subjects: 0
Study: 21194693

Group type: EXPERIMENTAL
Intervention: 15 mg lycopene daily for 8 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 6 mg lycopene daily for 8 weeks
Number of subjects: 126
Study: 18321372

Group type: EXPERIMENTAL
Intervention: Anterior approach technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional liver resection
Number of subjects: 150
Study: 17128339

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (part of the WHO trial for prevention of pre-eclampsia)
Number of subjects: 7993
Study: 13678475

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg once weekly
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Risedronate (RIS) 5 mg daily
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 549
Study: 11139370

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 9003923

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 353

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (Magnevist)
Number of subjects: 353
Study: 1467102

Group type: EXPERIMENTAL
Intervention: 22-gauge Whitacre needle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre needle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 26-gauge Quincke needle
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: More than two needle insertions
Number of subjects: 150

Group type: COMPARATOR
Intervention: Two or less needle insertions
Number of subjects: 150
Study: 6426377

Group type: EXPERIMENTAL
Intervention: Self-care medication program
Number of subjects: 0
Study: 30767274

Group type: EXPERIMENTAL
Intervention: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median])
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 117

Group type: COMPARATOR
Intervention: Eculizumab (for patients who received placebo during REGAIN)
Number of subjects: 117
Study: 30266120

Group type: EXPERIMENTAL
Intervention: Phacoemulsification combined with intraocular lens implantation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 152
Study: 28163732

Group type: EXPERIMENTAL
Intervention: Standard physical therapy and dry needling (DN)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 58
Study: 24142752

Group type: EXPERIMENTAL
Intervention: Centre-based cardiac rehabilitation (Group A)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hybrid model of training (Group B)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both groups (Group A and Group B)
Number of subjects: 53
Study: 22324419

Group type: EXPERIMENTAL
Intervention: ICP-ABP wave amplitude correlation (IAAC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pressure reactivity index (PRx)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: IAAC with average ≥ 0.2
Number of subjects: 94
Study: 19678781

Group type: EXPERIMENTAL
Intervention: Sour tea (Hibiscus sabdariffa), consumed two times a day for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Black tea, consumed two times a day for 1 month
Number of subjects: 60
Study: 17475954

Group type: EXPERIMENTAL
Intervention: Preoperative hepatobiliary scintigraphy measuring (99m)Tc-mebrofenin uptake in the future remnant liver.
Number of subjects: 46

Group type: COMPARATOR
Intervention: CT volumetric measurement of the future remnant liver.
Number of subjects: 46
Study: 14996106

Group type: EXPERIMENTAL
Intervention: Tetracaine gel (4% w/w)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle (placebo) gel
Number of subjects: 42
Study: 11426362

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (group C, n = 57)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Roller pump (group R, n = 56)
Number of subjects: 113
Study: 8996118

Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized peripheral-blood progenitor cell transplantation (PBPCT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 58
Study: 8315224

Group type: EXPERIMENTAL
Intervention: Oral arginine (3 g) plus lysine (3 g) taken twice daily for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo capsules taken twice daily for 14 days
Number of subjects: 16
Study: 3732582

Group type: EXPERIMENTAL
Intervention: Cefoxitin administered according to a three-dose, 12 h regimen, first injection given immediately after clamping of the umbilical cord.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cefoxitin group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 30588573

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (OAC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC)
Number of subjects: 97
Study: 27834756

Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 57

Group type: COMPARATOR
Intervention: ERT
Number of subjects: 57
Study: 27100025

Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Robotic gastrecty
Number of subjects: 311

Group type: COMPARATOR
Intervention: Open gastrectomy
Number of subjects: 311
Study: 23347094

Group type: EXPERIMENTAL
Intervention: Real-time visual feedback on knee abduction moments during double-leg jump landings
Number of subjects: 21

Group type: COMPARATOR
Intervention: No real-time feedback during double-leg jump landings (Control)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 21
Study: 22060105

Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.15 U/kg/die for 18 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 34
Study: 18972170

Group type: EXPERIMENTAL
Intervention: CA 19-9 velocity
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Baseline CA 19-9 levels
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CA 19-9 velocity at disease progression
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 96
Study: 17223061

Group type: EXPERIMENTAL
Intervention: Instant vision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patching
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 60
Study: 14980293

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylxanthines
Number of subjects: 0
Study: 12101333

Group type: EXPERIMENTAL
Intervention: Closed-suction (Jackson-Pratt) drains inserted into the peritoneal cavity and cul-de-sac
Number of subjects: 324

Group type: COMPARATOR
Intervention: No drains
Number of subjects: 324
Study: 10519166

Group type: EXPERIMENTAL
Intervention: Cutaneous aspirin (750 mg/day for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cutaneous aspirin
Number of subjects: 0
Study: 7627341

Group type: EXPERIMENTAL
Intervention: Normocaloric meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric, isobulk meal
Number of subjects: 0
Study: 1674632

Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol (6 mg)
Number of subjects: 17
Study: 7014105

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg chlorthalidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide after 100 mg chlorthalidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100 mg chlorthalidone after 40 mg xipamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg xipamide and 100 mg chlorthalidone
Number of subjects: 0
Study: 31475696

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of lidocaine in the sphenopalatine ganglion (IL; n=18)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endoscopic application of topical lidocaine over sphenopalatine ganglion (TL; n=7)
Number of subjects: 25
Study: 31111591

Group type: EXPERIMENTAL
Intervention: e‐SBIRT (n = 143)
Number of subjects: 439

Group type: COMPARATOR
Intervention: EUC (n = 151)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: SBIRT (n = 145)
Number of subjects: 439
Study: 28091647

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched spread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular spread
Number of subjects: 0
Study: 26452230

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy plus electrical stimulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Constraint‐induced movement therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional occupational therapy
Number of subjects: 68
Study: 23695232

Group type: EXPERIMENTAL
Intervention: Garenoxacin (GRNX) 400 mg/day for 4 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: SBT/ABPC (sulbactam/ampicillin) 6 g/day for 3 days followed by continuous administration for 4 days
Number of subjects: 108
Study: 21293305

Group type: EXPERIMENTAL
Intervention: High-load (HL) squat protocol (3 repetitions at 90% 1RM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-volume (HV) squat protocol (12 repetitions at 37% 1RM)
Number of subjects: 11
Study: 19660516

Group type: EXPERIMENTAL
Intervention: Tooth Mousse (CPP-ACP paste) applied for 3 min at 0, 8, 24, and 36 h after demineralization with soft drink (Coca Cola)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tooth Mousse (CPP-ACP paste) applied for 3 min without prior demineralization (intact enamel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Demineralization with soft drink (Coca Cola) (4 intervals of 2 min)
Number of subjects: 30
Study: 18693598

Group type: EXPERIMENTAL
Intervention: Modified Ultrafiltration (MUF)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study: 15296473

Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate), n=34
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg), n=37
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg), n=40
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no active treatment), n=35
Number of subjects: 146
Study: 10924298

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Ticlopidine (2x250 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Phenprocoumon (INR 2.0-3.0) with Dipyridamole (3x160 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C-reactive protein plasma levels
Number of subjects: 40
Study: 8820550

Group type: EXPERIMENTAL
Intervention: Unemployed subjects
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Part-time employment subjects
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Full-time employment subjects
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Second sample subjects
Number of subjects: 150
Study: 1576619

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Lactobacillus vaginal suppositories
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sterilized skim-milk suppositories
Number of subjects: 41
Study: 6732403

Group type: EXPERIMENTAL
Intervention: Group management plus feedback
Number of subjects: 48

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intensive educational program
Number of subjects: 48
Study: 3691914

Group type: EXPERIMENTAL
Intervention: 2 or 3% topical minoxidil applied twice daily for 12 months
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil (Regaine) applied twice daily for 1 year
Number of subjects: 56
Study: 31474161

Group type: EXPERIMENTAL
Intervention: Intravaginal CO2 laser therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28741622

Group type: EXPERIMENTAL
Intervention: CPP-115 (80 mg daily for 6, 10, or 14 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 27259391

Group type: EXPERIMENTAL
Intervention: Intracapsular tranexamic acid
Number of subjects: 131

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131
Study: 25480542

Group type: EXPERIMENTAL
Intervention: Low/moderate education group
Number of subjects: 1342

Group type: COMPARATOR
Intervention: High education group
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Attitude towards consuming vegetables and availability of vegetables at home
Number of subjects: 1342